Deals this week: AntriaBio, Race Oncology, Invenra


AntriaBio has announced the private placement of 4.5 million shares of its common stock, priced at $1 a share, to raise $4.5m in gross proceeds.

The US-based clinical-stage biopharmaceutical company plans to use the funds for general corporate purposes.

Australian speciality pharmaceutical company Race Oncology has announced the private placement of 12.5 million shares priced at A$0.2 ($0.16) a share to raise gross proceeds of A$2.5m ($1.78m).

Race Oncology plans to use the funds for the launch of its chemotherapy drug, Bisantrene.

Invenra has formed a partnership with Merck & Co. to engage in the discovery of therapeutic antibodies identified by the latter.

The agreement will enable Invenra to utilise the mAbSeq technology to progress its antibody discovery.

"Australian speciality pharmaceutical company Race Oncology has announced the private placement of 12.5 million shares priced at A$0.2 ($0.16) a share to raise gross proceeds of A$2.5m ($1.78m)."

Invenra is an antibody discovery and development company based in the US.

Silk Road Medical, a US-based R&D services provider for neurovascular diseases, has secured $47m in a venture financing round led by Norwest Venture Partners.

The company will use the funds to move its proprietary ENROUTE family of products towards commercialisation stage.

Shenzhen Kangtai Biological Products has announced a public offering of convertible bonds to raise gross proceeds of up to CNY356.6m ($52.65m).

Based in China, Shenzhen Kangtai specialises in the research, development and production of vaccines and other products.